Preliminary results indicated that BRAF inhibitors, such as Dabrafenib or Vemurafenib, are well tolerated in pediatric patients with BRAFV600-positive high-grade gliomas and induce a significant number of patients’ durable objective responses [413,416]. This evidence concerns the gene BRAF and central nervous system cancer.